| 1 |
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
Irene Litvan, Jennifer G. Goldman, Alexander I. Tröster et al. · Movement Disorders
Open access |
24 Jan 2012 |
2,583 |
| 2 |
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Günter U. Höglinger et al. · Movement Disorders
Open access |
3 May 2017 |
2,430 |
| 3 |
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
Ludovico Cantuti‐Castelvetri et al. · Science
Open access |
20 Oct 2020 |
2,038 |
| 4 |
Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance
Richard P. Allen, Daniel L. Picchietti, Diego Garcı́a-Borreguero et al. · Sleep Medicine
Open access |
17 May 2014 |
1,617 |
| 5 |
The ubiquitin pathway in Parkinson's disease
Elisabeth Leroy, Rebecca L. Boyer, Georg W. J. Auburger et al. · Nature
|
Oct 1998 |
1,582 |
| 6 |
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
Ronald B. Postuma et al. · Brain
Open access |
26 Jan 2019 |
1,142 |
| 7 |
A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease
Alexander A. Zimprich et al. · The American Journal of Human Genetics
Open access |
Jul 2011 |
915 |
| 8 |
MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
Irene Litvan, Dag Aarsland, Charles H. Adler et al. · Movement Disorders
Open access |
9 Jun 2011 |
810 |
| 9 |
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew D. Siderowf et al. · The Lancet Neurology
Open access |
13 Apr 2023 |
744 |
| 10 |
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
KENNETH L. MAREK et al. · Annals of Clinical and Translational Neurology
Open access |
31 Oct 2018 |
717 |
| 11 |
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions
Juliane Winkelmann et al. · Nature Genetics
|
18 Jul 2007 |
708 |
| 12 |
CSF and blood biomarkers for Parkinson's disease
Lucilla Parnetti, Lorenzo Gaetani, Paolo Eusebi et al. · The Lancet Neurology
Open access |
11 Apr 2019 |
692 |
| 13 |
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer, Joseph J. Locascio, Walter Schulz‐Schaeffer et al. · The Lancet Neurology
|
12 Feb 2011 |
634 |
| 14 |
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Tanya Simuni et al. · The Lancet Neurology
Open access |
22 Jan 2024 |
626 |
| 15 |
The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder
Anna Heintz‐Buschart, Urvashi Pandey, Tamara Wicke et al. · Movement Disorders
Open access |
26 Aug 2017 |
575 |
| 16 |
A Practical Guide to Immunoassay Method Validation
Ulf Andréasson et al. · Frontiers in Neurology
Open access |
19 Aug 2015 |
559 |
| 17 |
Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
Mohammad Shahnawaz, Takahiko Tokuda, Masaaki Waragai et al. · JAMA Neurology
Open access |
5 Dec 2016 |
521 |
| 18 |
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER)
Claudia Trenkwalder, Bryan Kies, Monika Rudzińska et al. · Movement Disorders
Open access |
18 Nov 2010 |
443 |
| 19 |
Parkinson's disease sleep scale—validation of the revised version PDSS‐2
Claudia Trenkwalder, Ralf Kohnen, Birgit Högl et al. · Movement Disorders
|
10 Feb 2011 |
437 |
| 20 |
Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies
Anne Stuendl, Marcel Kunadt, Niels Kruse et al. · Brain
Open access |
8 Dec 2015 |
436 |
| 21 |
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Stefanie Theresa Jost et al. · Movement Disorders
ReviewOpen access |
5 May 2023 |
390 |
| 22 |
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Brit Mollenhauer, Valerie Cullen, Ilana L. Kahn et al. · Experimental Neurology
|
15 Jun 2008 |
388 |
| 23 |
Restless legs syndrome associated with major diseases
Claudia Trenkwalder, Richard P. Allen, Birgit Högl et al. · Neurology
Open access |
4 Mar 2016 |
374 |
| 24 |
Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update
Marta del Campo, Brit Mollenhauer, Antonio Bertolotto et al. · Biomarkers in Medicine
|
Aug 2012 |
361 |
| 25 |
Trial of Cinpanemab in Early Parkinson’s Disease
Anthony E. Lang et al. · New England Journal of Medicine
Open access |
3 Aug 2022 |
360 |
| 26 |
The restless legs syndrome
Claudia Trenkwalder, Walter Paulus, Arthur Scott Walters · The Lancet Neurology
|
19 Jul 2005 |
353 |
| 27 |
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Sebastian Schade, Brit Mollenhauer, Claudia Trenkwalder · Movement Disorders Clinical Practice
Open access |
26 Feb 2020 |
349 |
| 28 |
Summary of the recommendations of the EFNS / MDS ‐ ES review on therapeutic management of P arkinson's disease
Joaquim José Ferreira et al. · European Journal of Neurology
|
22 Dec 2012 |
345 |
| 29 |
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
Regina Katzenschlager, Werner H Poewe, Olivier Rascol et al. · The Lancet Neurology
Open access |
25 Jul 2018 |
334 |
| 30 |
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Piotr Lewczuk et al. · The World Journal of Biological Psychiatry
Open access |
27 Oct 2017 |
321 |
| 31 |
Restless legs syndrome: pathophysiology, clinical presentation and management
Claudia Trenkwalder, Walter Paulus · Nature Reviews Neurology
Review |
Jun 2010 |
308 |
| 32 |
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity
Nadiya M. Teplyuk, Brit Mollenhauer, G. Gabriely et al. · Neuro-Oncology
Open access |
4 Apr 2012 |
304 |
| 33 |
Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease
Pablo Martínez‐Martín, Cristian Falup Pecurariu, Per Odin et al. · Journal of Neurology
|
11 Jan 2012 |
292 |
| 34 |
Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine – International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute
Diego Garcı́a-Borreguero, Richard P. Allen, Ralf Kohnen et al. · Sleep Medicine
|
4 Jun 2007 |
286 |
| 35 |
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome
Barbara Schormair et al. · Nature Genetics
Open access |
20 Jul 2008 |
286 |
| 36 |
Comorbidities, treatment, and pathophysiology in restless legs syndrome
Claudia Trenkwalder, Richard P. Allen, Birgit Högl et al. · The Lancet Neurology
Open access |
20 Sep 2018 |
276 |
| 37 |
Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype
Georgia Minakaki et al. · Autophagy
Open access |
4 Dec 2017 |
275 |
| 38 |
Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations
Birgit Högl, Isabelle Arnulf, Cynthia L. Comella et al. · Movement Disorders
|
7 Oct 2010 |
270 |
| 39 |
Absence of an Orphan Mitochondrial Protein, C19orf12, Causes a Distinct Clinical Subtype of Neurodegeneration with Brain Iron Accumulation
Monika Hartig et al. · The American Journal of Human Genetics
Open access |
Oct 2011 |
270 |
| 40 |
King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation
К. Ray Chaudhuri, Alexandra Rizos, Claudia Trenkwalder et al. · Movement Disorders
Open access |
11 Jun 2015 |
267 |
| 41 |
Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice
Claudia Trenkwalder, Wayne A. Hening, Pasquale Montagna et al. · Movement Disorders
Open access |
16 Oct 2008 |
263 |
| 42 |
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease
Oliver Riedel, Jens Klotsche, Annika E. Spottke et al. · Journal of Neurology
|
5 Feb 2010 |
261 |
| 43 |
Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation
Diana F. Lázaro, Eva Ferreira Rodrigues, Ramona Langohr et al. · PLoS Genetics
Open access |
13 Nov 2014 |
259 |
| 44 |
Cognitive impairment in 873 patients with idiopathic Parkinson's disease
Oliver Riedel, Jens Klotsche, Annika E. Spottke et al. · Journal of Neurology
Open access |
18 Jan 2008 |
255 |
| 45 |
Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis
Barbara Schormair et al. · The Lancet Neurology
ReviewOpen access |
13 Oct 2017 |
247 |
| 46 |
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group
Carlos Hugh Schenck et al. · Sleep Medicine
Open access |
22 Jul 2013 |
240 |
| 47 |
Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology
Kathrin Doppler, Sönke Ebert, Nurcan Üçeyler et al. · Acta Neuropathologica
Open access |
30 Apr 2014 |
237 |
| 48 |
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
The Parkinson’s Progression Marker Initiative et al. · Acta Neuropathologica
Open access |
28 Mar 2016 |
229 |
| 49 |
Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension
Claudia Trenkwalder, Heike Beneš, Ludger Grote et al. · The Lancet Neurology
|
17 Oct 2013 |
229 |
| 50 |
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [ 123 I]FP‐CIT SPECT
Vicky L. Marshall et al. · Movement Disorders
|
2 Jan 2009 |
212 |